Cryptosporidium meleagridis: Infectivity in Healthy Adult Volunteers

Cynthia L. Chappell,* Pablo C. Okhuysen, Rebecca C. Langer-Curry, Donna E. Akiyoshi, Giovanni Widmer, and Saul Tzipori
Center for Infectious Diseases, The University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas; Department of Internal Medicine, The University of Texas Health Science Center at Houston, Medical School, Houston, Texas; Department of Biomedical Sciences, Tufts University Cummings School of Veterinary Medicine, North Grafton, Massachusetts

Abstract. Most Cryptosporidium infections in humans are caused by C. parvum or C. hominis. However, genotyping techniques have identified infections caused by unusual Cryptosporidium species. Cryptosporidium meleagridis has been identified in ≤1% of persons with diarrhea, although prevalence is higher in developing nations. We examined the infectivity of C. meleagridis in healthy adults. Five volunteers were challenged with 10⁵ C. meleagridis oocysts and monitored six weeks for fecal oocysts and clinical manifestations. Four volunteers had diarrhea; three had detectable fecal oocysts; and one infected volunteer remained asymptomatic. Fecal DNA from two volunteers was amplified by using a polymerase chain reaction specific for the Cryptosporidium small subunit ribosomal RNA gene. Nucleotide sequence of these amplicons was diagnostic for C. meleagridis. All infections were self-limited; oocysts were cleared within ≤12 days of challenge. These studies establish that healthy adults can be infected and become ill from ingestion of C. meleagridis oocysts.

INTRODUCTION

Cryptosporidium spp. are coccidian parasites that cause diarrheal illness in a wide range of animal species. In humans, C. parvum and C. hominis are responsible for most cases of cryptosporidiosis, and C. meleagridis, C. canis, and C. felis make up the remainder.¹² Cryptosporidium meleagridis appears to be prominent among unusual isolates and in some geographic areas can be as common as C. parvum.³⁵

Cryptosporidium meleagridis was originally isolated from a turkey and has subsequently been found in other avian species, including parrots, red-legged partridges, and chickens.⁴⁻⁶ The infection has been experimentally established in immunosuppressed mice,⁹,¹⁰ and C. meleagridis isolated from a human has been successfully passaged in chickens, mice, gnotobiotic piglets, and calves.¹¹ In those animals, the infectivity and virulence of C. meleagridis was similar to that of C. parvum.

Although the first reported human case of C. meleagridis was in a human immunodeficiency virus (HIV)–positive person from Kenya,¹² the infection has since been identified in immunocompetent and immunosuppressed humans throughout the world.¹⁻³,⁵⁻¹⁰,¹²⁻³⁴ Furthermore, the finding of C. meleagridis in humans across geographically distinct regions, such as Peru, Spain, Kenya, Thailand, and Japan, affirmed the potential of the parasite as a public health concern.⁵,⁻²³,²⁷ Although widespread geographically, C. meleagridis is frequently attributed to only a small proportion (<1%) of Cryptosporidium cases from large populations with diarrhea.²⁻⁴,¹⁴,³² Since 2000, more than 200 C. meleagridis infections have been reported.²⁻⁵,¹²⁻³⁴ Immune status was known in 135 C. meleagridis infections, and of those, 61.5% were in immunocompromised persons.

Similar to other Cryptosporidium species, the severity of C. meleagridis infection varies with the general health of the host and can range from asymptomatic shedding of oocysts to death associated with severe fluid and weight loss.¹⁹,²⁰ Where studied, no differences in illness among adults have been noted between C. meleagridis and C. parvum or C. hominis. However, in HIV-positive children, infections with C. meleagridis were more likely to cause diarrhea than infection with C. parvum or C. hominis.³

Most C. meleagridis cases have been identified in diarrhea studies. However, five asymptomatic cases, all in children, have also been described.¹³,³⁴ These asymptomatic cases suggest that the actual number of C. meleagridis infections may be higher than reported.

Current literature on C. meleagridis in humans has focused on naturally acquired infections among immunocompetent and immunocompromised persons. Many of these investigations analyzed only those stool samples from patients with diarrhea. Thus, the true prevalence of infection is difficult to assess. Furthermore, the overall prevalence of C. meleagridis may be underestimated because the morphology of oocysts by acid-fast staining is similar to that of C. hominis and C. parvum, and detection by immunofluorescent-based assays is based on the recognition of a shared antigen among the three species. Furthermore, conventional polymerase chain reaction (PCR)–based assays used in many of the studies may be unable to distinguish it from C. parvum.³⁵

Previous human challenge studies have established infectivity and illness outcomes for C. parvum and C. hominis isolates.³⁶⁻⁻⁴⁰ The present study was designed 1) to establish the susceptibility of healthy, adult volunteers to C. meleagridis infection after the ingestion of a known dose of oocysts and 2) to describe microbiologic and clinical outcomes of those who became infected. This study represents the first experimental challenge of C. meleagridis in humans.

MATERIALS AND METHODS

Volunteer selection. Volunteers 18–50 years of age were solicited at the Texas Medical Center in Houston and screened for general health status as described.⁴⁰ All studies described herein were reviewed and approved by the Committee for Protection of Human Subjects at The University of Texas Health Science Center at Houston. Informed consent was obtained for initial medical evaluation and blood draw and again before challenge with C. meleagridis oocysts.

Volunteer monitoring and sample collection. Volunteers were challenged and monitored in the University Clinical Research Center (Hermann Memorial Hospital, Houston, TX) as described.⁴⁰ Briefly, each volunteer received 10⁵
C. meleagridis oocysts instilled in a gelatin capsule. Each person was examined daily for 14 days and three times per week for four weeks. All stool samples were collected for the first 14 days and twice per week thereafter. Stool samples were transported on ice to the laboratory and were diluted 1:4 in buffered formalin for storage at 4°C until assayed. Definitions for diarrhea, illness attack rate, Cryptosporidium infection, cryptosporidiosis, gastrointestinal symptoms, and duration of diarrhea used in this study have been described.37,39

**Oocyst isolation and preparation.** Cryptosporidium meleagridis isolate TU1867 was isolated from the stool of a child with diarrhea and identified as *C. meleagridis* by using the outer cell wall protein (COWP) marker by PCR/restriction fragment length polymorphism (RFLP).33 Isolate TU1867 has been established in the gnotobiotic pig model and passaged repeatedly.33 Oocysts were purified, transported to Houston in 2% potassium dichromate, and tested for microbiologic agents as described.40 To further ensure the safety of the inoculum, two tests for the presence of the HIV genome were carried out in the retrovirus laboratory of Dr. Blaine Hollinger (Baylor College of Medicine, Houston, TX). The first test examined the DNA from disrupted *C. meleagridis* oocysts, which had been prepared in the same way as the inoculum for volunteer studies. For the second test, oocysts were inoculated onto human enterocytes (HCT-8 cells) and cultured for 24–48 hours. Cells were delivered to the Baylor laboratory where DNA was extracted for testing. All tests of the disrupted or cultured parasites were negative for HIV.

Within 48 hours of volunteer challenge, purified *C. meleagridis* oocysts were examined for excystation rate and adjusted to a concentration of approximately 10⁶ oocysts/10 μL in preparation for volunteer challenge as described.40

**Detection of oocysts.** Every fecal sample collected from challenged volunteers over the six-week monitoring period was examined by enzyme immunoassay (EIA) and immunofluorescent assay (IFA) for oocysts. The EIA (SPECTRAFluor Plus; JVD Research Inc., Carlsbad, CA) was carried out and interpreted as per manufacturer’s instructions. For the IFA, 5 μL of formalin-fixed stool was added to each well of three wells on a treated microscope slide (SuperStick Slides; Waterborne, Inc., New Orleans, LA) and dried for 1.5 hours at room temperature. Each well then received 50 μL of fluorescein isothiocyanate–conjugated, monoclonal IgM against *Cryptosporidium* (1:1000; Cellabs Pty. Ltd., Brookvale, New South Wales, Australia) and incubated in a humidified chamber in the dark for 30 minutes. Slides were then gently rinsed with 0.15 M phosphate-buffered saline, pH 7.2, and allowed to air dry. The entire well of the slide was examined by epifluorescence microscopy (20×), and fluorescing oocysts were counted. The mean number of oocysts from three wells was expressed per milliliter after adjusting for the 1:4 formalin dilution. Oocyst counts per stool were estimated as described.41 Oocyst counts from each stool sample were summed to estimate the total oocysts shed during the monitoring period.

To genotype the oocysts excreted by volunteers, DNA was extracted from 200 μL of fecal slurry by using the FastDNA Spin Kit for Soil (MP Biomedicals, Illkirch, France). DNA was recovered in 50 μL of water. A volume of 1 μL of DNA was amplified in a nested PCR protocol specific for a portion of the small-subunit ribosomal RNA (SSU rRNA) as described42 and later amended.35 The primary PCR product was diluted 1:200 or 1:400, and 1 μL of this dilution was used as template in the secondary reaction.

**RESULTS**

**Inoculum.** Cryptosporidium meleagridis oocysts used in the study showed no observable changes in the COWP PCR-RFLP profile as they were passaged through different porcine hosts. In addition, there was no indication of the presence of a subpopulation of oocysts or of contamination with *C. parvum* laboratory isolates. Two batches of oocysts were used in the study. At the time of challenge, the oocysts were within six weeks of production in the gnotobiotic piglet and had excystation rates of 48.6% and 66%, respectively. Mean ± SD oocyst counts in the inocula were 103,152 ± 10,685 and 100,170 ± 6,108, both within 10.3% or less of the target number (10⁵).

**Challenge outcomes.** Five healthy volunteers were enrolled in the study during September–December 2003. Volunteer ages ranged from 22 to 33 years (median = 25 years), and four (80%) of the five volunteers were men. All five volunteers were Caucasian; none had *Cryptosporidium*-specific serum IgG by enzyme-linked immunosorbent assay before challenge.

All five volunteers had evidence of infection by either clinical or microbiologic measures or both (Table 1), indicating that the inoculum (10⁵ oocysts) met or exceeded the 100% infectious dose for this parasite. Three (60%) volunteers had a diarrheal illness, yielding an 80% illness attack rate. Two of the four volunteers with diarrhea had detectable oocysts, and two did not. One volunteer had no unformed stools or symptoms while shedding low, but detectable, numbers of oocysts.

Overall, diarrheal illnesses were characterized by an incubation period of 5.3 days (range = 4–7 days) and passage of approximately eight unformed stools (range = 3–15 stools) in a period of 77 hours (3.2 days; range = 50–105 hours) (Figure 1). Total weight of unformed stools during the diarrheal episode ranged from 0.44 to 3.0 kg (mean = 1.2 kg). In three

<table>
<thead>
<tr>
<th>Volunteer no.</th>
<th>Onset (dpi)</th>
<th>Duration (hours)</th>
<th>Total no. unformed stools</th>
<th>Total stool weight (g)</th>
<th>GI symptoms</th>
<th>Oocyst shedding</th>
</tr>
</thead>
<tbody>
<tr>
<td>180</td>
<td>4</td>
<td>61</td>
<td>9</td>
<td>599.5</td>
<td>AB pain</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(day 4); nausea (day 6); gas (days 1–6)</td>
<td>6.41</td>
</tr>
<tr>
<td>181</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Gas (days 5, 7)</td>
<td>3</td>
</tr>
<tr>
<td>182</td>
<td>7</td>
<td>107</td>
<td>15</td>
<td>2,998.9</td>
<td>Gas and fecal urgency (days 7–11)</td>
<td>8</td>
</tr>
<tr>
<td>183</td>
<td>4</td>
<td>90</td>
<td>4</td>
<td>758.5</td>
<td>Gas (days 2–4, 8)</td>
<td>3</td>
</tr>
<tr>
<td>184</td>
<td>6</td>
<td>50</td>
<td>3</td>
<td>439.8</td>
<td>AB cramps and gas (day 6)</td>
<td>8.65</td>
</tr>
</tbody>
</table>

* dpi = day post-challenge; GI = gastrointestinal; AB = abdominal; NA = not available.
Volunteer 180. Volunteer 180 had one episode of diarrheal illness beginning on day 4 post-challenge that lasted 2.5 days. A total of nine unformed stools were passed: four on day 4 (total weight = 163.8 g), two on day 5 (total weight = 261.3 g), and three on day 6 (weight = 174.5 g). Oocysts were excreted beginning on day 4 and continued one day after resolution of diarrheal and symptoms. No oocysts were detected in 12 subsequent stool samples.

Volunteer 181. Volunteer 181 did not meet the criteria for a diarrheal illness, but had a microbiologically confirmed infection. Oocysts were excreted for four days beginning on day 3 post-challenge. Five unformed stools were passed during the oocyst shedding period: one on day 3 (weight = 91.9 g), one on day 5 (weight = 77.2 g), two on day 6 (total weight = 136.4 g), and one on day 7 (weight = 77.8 g).

Volunteer 182. Volunteer 182 had diarrheal illness beginning on day 7 post-challenge that lasted 4.5 days. Seventeen unformed stools were passed during the diarrheal illness: one on day 2 (total weight = 141.1 g), one on day 4 (total weight = 188.7 g), five on day 7 (total weight = 847.7 g), five on day 8 (total weight = 955.4 g), one on day 9 (total weight = 218.0 g), one on day 10 (total weight = 154.2 g), and three on day 11 (total weight = 823.4 g). Oocysts were shed for three days during the illness. After day 10, no oocysts were detected in any of the 17 submitted stool samples.

Volunteer 183. Volunteer 183 had diarrheal illness beginning on day 4 post-challenge that lasted through day 7. Four unformed stools occurred during the illness: one on day 4 (total weight = 248.9 g), two on day 6 (total weight = 354.4 g), and one on day 7 (total weight = 155.2 g). Gas was reported before and during the diarrheal episode with no other gastrointestinal symptoms present. Twenty stool samples were uniformly negative for oocysts.

Volunteer 184. Volunteer 184 had diarrheal illness on days 6–8 after challenge. Three unformed stools were documented during the illness: two on day 6 (total weight = 305.0 g) and one on day 8 (total weight = 134.7 g). Abdominal cramping and gas were reported on day 6. No oocysts were detected in any of the 17 submitted stool samples.

Fecal DNA from two oocyst-shedding volunteers was amplified by using a nested PCR protocol specific for the SSU rRNA gene. A third sample from volunteer 181 failed to amplify. A PCR product approximating the expected size of 833 basepairs was obtained from volunteers 180 and 182. Sequences of 690 basepairs and 733 basepairs, respectively, were obtained from these PCR products by sequencing both strands. These sequences were 100% identical with the C. meleagridis SSU rRNA sequences found in GenBank, such as accession no. HM116384. A control sample was PCR negative.

**DISCUSSION**

The C. meleagridis isolate TU1867 used in the study was previously identified by COWP PCR-RFLP and nested PCR of the SSU rRNA gene. The resulting 833-basepair fragment from the nested PCR was digested with Ase I, which can distinguish at least nine Cryptosporidium species and C. parvum genotypes. The Ase I RFLP profile of the TU1867 isolate was identical with that reported for C. meleagridis and did not change as the isolate was passaged through different hosts. Also, a second Cryptosporidium population was not detected. The nested PCR products from the original human sample and from the animal host passages were previously cloned and sequenced. These sequences were invariant and were identical with previously published sequences of C. meleagridis.

In the earlier study, TU1867 was infectious when fed to interferon-γ knockout and immunosuppressed C57BL/6 mice, 2–7-day-old chicks and turkey poult,s and colostrum-fed calves. Infection of these hosts indicated that C. meleagridis was readily transmissible between mammalian and avian species. However, diarrhea without appreciable signs of dehydration was consistently observed only in infected piglets. In contrast, no clinical signs developed in the infected colostrum-fed calves, even though excretion of oocysts was evident. In comparison, diarrhea has been associated with C. meleagridis infection in immunocompromised and ostensibly healthy humans. However, many of the symptomatic infections reported in immunocompetent persons have been in children and/or in populations that may be undernourished or infected with other pathogens, including chronic parasites.

Although these earlier reports of C. meleagridis indicated susceptibility in humans, infectivity and/or illness in healthy adults was less clear and was the focus of the present study. On the basis of previous findings in volunteers who received C. parvum or C. hominis isolates, a C. meleagridis inoculum was chosen that would likely exceed the 100% infectious dose. This oocyst dose resulted in infection and/or illness in all of the volunteers, thus establishing the susceptibility of healthy adults to C. meleagridis infection. All volunteers had no evidence of previous infection as assessed by the absence of serum antibodies by enzyme-linked immunosorbent assay.
It is not known if prior exposure would have provided any protection from subsequent challenge as has been shown with *C. parvum*. Furthermore, because the present study used only one oocyst dose, no estimation of a 50% infectious dose can be made for the TU1867 isolate. It is likely that the 50% infectious dose is far less than the 100 oocysts used.

A self-limited diarrhea was observed in four of the five volunteers in contrast to the paucity of symptoms found earlier in animal studies. In those experiments, only the gnotobiotic piglets had diarrhea, although the neonatal or immunosuppressed animals excreted oocysts. Interestingly, volunteer 182 excreted 100-fold more oocysts than the other volunteers with detectable oocysts. This increased oocyst excretion was associated with longest duration (107 hours) and the greatest severity (approximately 3-kg stool weight and 15 unformed stools).

Volunteers had days of no detectable oocysts between days when large numbers were shed. Also, one of the volunteers shed oocysts detectable by EIA but not by IFA. These results are not particularly surprising because oocyst shedding can be near or below the limit of detection on some days and for one or both assays. This finding may also explain why volunteer 181 was PCR negative. In our experience and in other laboratories, detection limits of the IFA are in the range of 1000 oocysts/mL. The absorbance value of the EIA for the EIA-positive/IFA-negative volunteer was nearer the manufacturer’s cutoff value than for others volunteers, which suggested a lower intensity of infection.

The five volunteers that took part in this study were relatively young adults in excellent health. Each received an oocyst dose that would likely be much higher than encountered in a community setting. Nevertheless, the diarrheal illness that they experienced was similar to the illness reported in previous volunteer studies of *C. parvum* or *C. hominis*. Furthermore, the present study used the same volunteer selection criteria and post-challenge monitoring used in previous volunteer studies of *C. parvum* or *C. hominis*. Thus, these earlier highly monitored volunteers may serve as a more apt comparison than in naturally acquired infections. The various microbiologic and clinical measures from the *C. meleagridis* volunteers were within ranges previously described for *C. parvum* and *C. hominis* isolates.

Our study firmly establishes that immunocompetent, healthy persons are susceptible to *C. meleagridis* infection. Our data further suggest that otherwise healthy persons who have a community-acquired infection will likely experience a mild, self-limited diarrheal disease and will be unlikely to seek medical attention. Furthermore, because current serologic studies of IgG against *Cryptosporidium* are not specific for the species of *Cryptosporidium* that elicited the response, the level of exposure to *C. meleagridis* in the community cannot presently be estimated. The human challenge studies are important for establishing susceptibility to infection and illness from these non-*C. parvum* species and for contributing to risk assessment and the setting of water quality regulatory standards.

Received November 24, 2010. Accepted for publication May 9, 2011.

Acknowledgments: We thank Susan Wu for assistance in preparation of the manuscript and Julia Dilo for expert laboratory support.

Financial support: This study was supported, in part, by the National Center for Environmental Research STAR Program of the Environmental Protection Agency (grant GR828035-01-0 to Cynthia L. Chappell), the National Institutes of Health General Clinical Research Centers (grant RR-02558), and the National Institute of Allergy and Infectious Diseases (grant AI52781 to Giovanni Widmer and grant NO1-AI-25466 to Saul Tzipori).

Authors’ addresses: Cynthia L. Chappell, Center for Infectious Diseases, University of Texas School of Public Health, Houston, TX, E-mail: cynthia.chappell@uth.tmc.edu; Pablo C. Okhuysen, Division of Infectious Diseases University of Texas Health Medical School, Houston, TX, E-mail: pablo.c.okhuysen@uth.tmc.edu; Rebecca C. Langer-Curry, Bayer CropScience Bioscience, Morrisville, NC, E-mail: becky.langer@bayer.com; Donna E. Akiyoshi, Giovanni Widmer, and Saul Tzipori, Department of Biomedical Sciences, Tufts University, North Grafton, MA, Emails: donna.akiyoshi@tufts.edu, giovanni.widmer@tufts.edu, and saul.tzipori@tufts.edu.

REFERENCES


